AI / Biotech

🔥 A DeepMind Spinout Just Raised $5 Billion, Biotech's Biggest Venture Round Ever

Isomorphic Labs, Google DeepMind's drug-design spinout, raised a $5 billion Series C, biotech's biggest venture round ever, with no drug yet in human trials.

A DeepMind Spinout Just Raised $5 Billion, Biotech's Biggest Venture Round Ever — Tech Arcade
Photo: Google DeepMind / Unsplash

Isomorphic Labs just closed a $5 billion Series C, and that single number makes it the largest venture round in the history of biotech (BioSpace).

Put it next to the old record and the gap is almost rude. When Altos Labs launched in 2022 with $3 billion, people called the figure absurd. Isomorphic beat that by two billion dollars in a single round, and it did so six months after raising $2.1 billion (RD World).

The company is a Google DeepMind spinout run by Nobel laureate Demis Hassabis. It has not yet put a single drug into a human being.

Investors just wrote the biggest cheque biotech has ever seen to a firm whose flagship product is still preclinical, betting that AI will crack drug discovery before the lab bills come due.

🧠 Why This Matters

Drug discovery is where money goes to die. The average new medicine takes more than a decade and north of a billion dollars, and roughly nine in ten candidates that reach human trials fail. Isomorphic’s pitch is that an AI which can predict how molecules behave shrinks the guesswork at the front of that pipeline, where most of the waste lives.

The company was carved out of DeepMind in 2021 on the back of AlphaFold, the protein-structure model that earned Hassabis a share of the 2024 Nobel Prize in Chemistry. Its drug-design engine, IsoDDE, proposes and refines molecules before anyone touches a pipette.

“Our drug design engine is generating molecules with unprecedented precision and speed.” — Sir Demis Hassabis, founder and CEO, Isomorphic Labs (TechFundingNews)

Five billion dollars is the market saying it believes him.

📊 Deep Dive

The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new backer and Alphabet writing another large cheque (TechFundingNews). Every existing investor re-upped, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

Here is how the cheque stacks up against the biggest moments in the field:

  • Isomorphic Labs, Series C: $5bn (Nov 2026) — the new record.
  • Altos Labs, launch: $3bn (2022) — the record it just broke.
  • Isomorphic Labs, Series B: $2.1bn (May 2026) — less than half the new round, raised only six months earlier.
  • Xaira Therapeutics, launch: over $1bn (Apr 2024) — the previous headline AI-bio bet.
  • Isomorphic, total since March 2025: at least $7.7bn — BioSpace’s running count.

Bloomberg reported on 4 November that the talks valued the company at roughly $50 billion, though Isomorphic has not confirmed a figure (TechFundingNews). Alphabet, per UK Companies House filings, still controls 75% or more of the shares and voting rights, so this is as much a bet on Google’s balance sheet as on a plucky startup.

⚠️ The Catch

Zero drugs in humans. That is the whole catch, and it is a large one.

Isomorphic says its internal oncology and immunology programmes have produced positive preclinical results, which is science-speak for “it worked in the lab, not in a person”. Preclinical wins do not establish safety or efficacy, and the graveyard of biotech is stacked with molecules that looked flawless until a human immune system got a vote.

Hassabis told Davos in January that the first trials would begin by the end of 2026, a target that had already slipped from an earlier end-of-2025 goal (RD World). It is now mid-November, and the clock is loud.

There is an openness catch too. AlphaFold’s code and model weights were released for non-commercial use. IsoDDE’s are not. Nature has reported the company has no plans to reveal its “secret sauce”, so the thing $5 billion is funding is a closed box to everyone outside the building.

🎯 What Happens Next

The money buys three things, in Hassabis’s framing: maturing IsoDDE, building infrastructure for AI-led bioengineering, and standing up the translational and clinical machinery needed to run real trials. He says the company has more than 20 programmes underway, and that the cash is for “driving our first therapeutic programs towards clinical trials” (TechFundingNews).

Watch for the first Investigational New Drug filing. The moment an Isomorphic molecule is cleared to dose a human, the story stops being about models and starts being about biology. Miss the end-of-2026 window, and the questions get sharper and the $50 billion starts to itch.

🧩 Bigger Picture

This is the clearest sign yet that the AI capital wave has reached the lab bench. The same funds underwriting frontier language models, Sequoia, a16z and Thrive among them, are now backing the idea that those models can design medicine rather than just hold a conversation.

“Discovering and developing new medicines is an optimization challenge of almost infinite scale.” — Neil Mehta, founder and managing partner, Greenoaks (TechFundingNews)

Isomorphic’s commercial model tells you how big the ambition is. It works with Eli Lilly, Novartis and Johnson & Johnson, but it is not renting out its AI by the token. It wants to own the drugs themselves, a far richer prize than a software subscription and a far longer road to walk.

Five billion dollars says the hard part of drug discovery is now a maths problem. The patients will be the ones who find out whether that is true.


Sources

❓ Quick answers

How much did Isomorphic Labs raise in its Series C?

Isomorphic Labs raised a $5 billion Series C announced on 17 November 2026, the largest venture round in biotech history, per BioSpace.

Who led Isomorphic Labs' $5 billion round?

Greenoaks and Sequoia Capital co-led it, with Andreessen Horowitz new and Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund returning (TechFundingNews, 17 Nov 2026).

Does Isomorphic Labs have any drugs in human trials?

No. As of November 2026 its oncology and immunology programmes are preclinical, and CEO Demis Hassabis said the first clinical trials were expected by the end of 2026.